Gallo D - Search Results

1

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer.

Buttarelli M, De Donato M, Raspaglio G, Babini G, Ciucci A, Martinelli E, Baccaro P, Pasciuto T, Fagotti A, Scambia G, Gallo D. Buttarelli M, et al. Among authors: gallo d. Cancers (Basel). 2020 Apr 14;12(4):966. doi: 10.3390/cancers12040966. Cancers (Basel). 2020. PMID: 32295169 Free PMC article.

2

Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.

Gallo D, Ferlini C, Distefano M, Cantelmo F, Gaggini C, Fattorossi A, Riva A, Bombardelli E, Proietti E, Mancuso S, Scambia G. Gallo D, et al. Cancer Chemother Pharmacol. 2000;45(2):127-32. doi: 10.1007/s002800050020. Cancer Chemother Pharmacol. 2000. PMID: 10663627

3

Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors.

Gallo D, Ferrandina G, Giacomelli S, Fruscella E, Zannoni G, Morazzoni P, Riva A, Bombardelli E, Mancuso S, Scambia G. Gallo D, et al. Cancer Lett. 2002 Dec 1;186(1):43-8. doi: 10.1016/s0304-3835(02)00326-9. Cancer Lett. 2002. PMID: 12183074

4

Second generation taxanes: from the natural framework to the challenge of drug resistance.

Ferlini C, Ojima I, Distefano M, Gallo D, Riva A, Morazzoni P, Bombardelli E, Mancuso S, Scambia G. Ferlini C, et al. Among authors: gallo d. Curr Med Chem Anticancer Agents. 2003 Mar;3(2):133-8. doi: 10.2174/1568011033353489. Curr Med Chem Anticancer Agents. 2003. PMID: 12678907 Review.

5

Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G. Ferlini C, et al. Among authors: gallo d. Mol Pharmacol. 2003 Jul;64(1):51-8. doi: 10.1124/mol.64.1.51. Mol Pharmacol. 2003. PMID: 12815160

6

Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.

Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E, Scambia G. Gallo D, et al. Eur J Cancer. 2003 Nov;39(16):2403-10. doi: 10.1016/s0959-8049(03)00624-5. Eur J Cancer. 2003. PMID: 14556934

7

Gemcitabine: current role and future options in the treatment of ovarian cancer.

Fruscella E, Gallo D, Ferrandina G, D'Agostino G, Scambia G. Fruscella E, et al. Among authors: d agostino g, gallo d. Crit Rev Oncol Hematol. 2003 Oct;48(1):81-8. doi: 10.1016/s1040-8428(03)00119-7. Crit Rev Oncol Hematol. 2003. PMID: 14585485 Review.

8

Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors.

Raspaglio G, Ferlini C, Mozzetti S, Prislei S, Gallo D, Das N, Scambia G. Raspaglio G, et al. Among authors: gallo d. Biochem Pharmacol. 2005 Jan 1;69(1):113-21. doi: 10.1016/j.bcp.2004.09.004. Biochem Pharmacol. 2005. PMID: 15588720

9

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G. Mozzetti S, et al. Among authors: gallo d. Clin Cancer Res. 2005 Jan 1;11(1):298-305. Clin Cancer Res. 2005. PMID: 15671559

10

The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G. Ferlini C, et al. Among authors: gallo d. Cancer Res. 2005 Mar 15;65(6):2397-405. doi: 10.1158/0008-5472.CAN-04-3065. Cancer Res. 2005. PMID: 15781655

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

686 results

Search Page

Filters